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TO EVALUATE THE PRESENCE OF CARDIOVASCULAR 
ABNORMALITIES AND ITS ASSOCIATION WITH THE SEVERITY 
OF AIRWAY OBSTRUCTION IN STABLE COPD PATIENTS 
 
ABSTRACT 
 
AIMS AND OBJECTIVES 
1. To evaluate the presence of cardiovascular abnormalities in stable COPD 
patients      
2. To correlate the cardiovascular abnormalities with severity of airway 
obstruction 
 
MATERIALS and METHODS 
 It  was an observational study done in department of pulmonary medicine, 
KMC/GTHTM, wherein 100 stable COPD patients, diagnosed and staged according 
to GOLD guidelines were evaluated by ECHO for cardiovascular abnormalities. Then 
the cardiovascular abnormalities were correlated with the severity of airway 
obstruction. Parameters assessed to find out the cardiovascular abnormalities were 
presence of pulmonary hypertension, TAPSE (systolic function of right ventricle) and 
Tei index (global function) of right ventricle ,Ejection fraction of left ventricle and 
presence of LVdiastolic dysfunction. 
 
RESULTS 
 On evaluation of 100 COPD patients, 54 Patients had pulmonary hypertension. 
Frequency of pulmonary hypertension were 2(16.66%), 8(25.8%), 31(79.4%) and 
13(72%) in mild, moderate, severe and very severe COPD respectively. In our study, 
TAPSE was within normal mean range in all patients. TEI index was abnormal in 59 
patients of which 3(25%), 13(41%), 30(76%) and 13(72%) in mild, moderate, severe 
and very severe COPD patients respectively. LV systolic function was preserved and 
27% had left ventricular diastolic dysfunction. Cardiac comorbidities increased with 
increase in severity of COPD. 
 CONCLUSION 
 Mortality and morbidity in COPD patients are mainly due to cardiac 
abnormalities rather than COPD itself, especially in moderate to severe COPD. In our 
study 59% had cardiac abnormalities and these patients are at a higher risk for death 
due to cardiac abnormalities. So, all stable COPD patients have to be subjected to 
routine ECHO to identify cardiac abnormalities early in the course of disease to 
reduce mortality due to cardiac abnormalities. 
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INTRODUCTION 
 
 GOLD defines “COPD, a common preventable and treatable disease, is 
characterised by persistent airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response in the airways and 
the lung to noxious particles or gases”1. Worldwide, COPD is a leading cause 
of death and disability. In 2020, it will be the 3rd leading cause of mortality 
and 5th in morbidity [2, 3]. The cost for caring of COPD patients continues to 
increase, with a significant proportion attributable to acute exacerbations 4 and 
comorbidities.  
 
 Globally, cigarette smoking is the most commonly encountered risk 
factor for COPD. Family history of COPD is a risk factor for COPD 
development, independent of family or personal smoking history, or childhood 
environmental tobacco exposure. The prevalence of COPD is approximately 
20% in smokers and 4% in nonsmokers5. Even though not all smokers develop 
COPD, smokers still lose lung function (60 mL/year FEV1) in a dose-
dependent manner6. “Second hand smoke” or “environmental tobacco smoke” 
exposure, outdoor pollution, and biomass smoke are the other factors 
associated with increased risk for COPD7, 8, 9. Smoke from biomass fuels used 
for cooking is an important risk factor of COPD in women in developing 
countries10.The attributable fraction of COPD due to cigarette smoking is 
approximately 80% to 90%, 11 while other risk factors contribute by 
approximately 15%. 
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 Genetic factors and gender also play a role. The strongest genetic risk 
factor that has been identified is mutation causing alpha-1-antitrypsin 
deficiency. The  nicotinic acetylcholine receptor CHRNA3/5, HHIP, and 
FAM13A loci appear to be associated with susceptibility of the disease12.The 
HHIP locus appears to be associated with the systemic components of COPD, 
frequency of COPD exacerbations, and FEV1/FVC ratio13,14.Women report 
more dyspnea, similar severity of cough, but less sputum than men15 and  more 
frequent exacerbations 16,17 . 
 
 Comorbidities, defined as other chronic medical conditions, including 
coronary artery disease, diabetes mellitus, skeletal muscle weakness, cachexia, 
osteoporosis and muscle weakness, are common in chronic obstructive 
pulmonary disease (COPD) with variable prevalence19.  
 
 Two theories have been put forth to explain the relationship between 
COPD and its manifestations and comorbidities. One view states “systemic 
‘‘spill-over’’ of the inflammatory and reparatory events occurring in the lungs 
of patients with COPD, with the disease remaining at the centre of the 
process”, whereas the other view states “pulmonary manifestations of COPD 
are one more form of expression of a ‘‘systemic’’ inflammatory state with 
multiple organ compromise” [20, 21]. The relationship between systemic effects 
and comorbidities of chronic obstructive pulmonary disease (COPD) is as 
depicted in the following picture. 
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Fig 1: Systemic effects and comorbidities of chronic obstructive 
pulmonary disease (COPD) 
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 Among the significant extra-pulmonary systemic comorbidities in 
COPD, cardiac manifestations are the most common. Up to 31% of those 
admitted in ICU as acute exacerbation of COPD might be due to cardiac 
comorbidity24.Majority of mortality in mild or moderate COPD are due to lung 
cancer and cardiovascular diseases, while in more advanced COPD, respiratory 
failure is the predominant cause25. The strongest predictors of CVD are severity 
of airway obstruction and age. Impaired lung function itself is an independent 
risk factor for increased cardiovascular mortality even when adjusted for 
smoking status26. It affects pulmonary blood vessels, right ventricle as well as  
left ventricle leading to development of pulmonary hypertension, right 
ventricular dysfunction, cor-pulmonale and left ventricular dysfunction  
too[22, 23]. 
 
 Hence assessment of cardiac condition in all COPD patients and 
identification of cardiac abnormalities early in the course of disease alters the 
mortality and morbidity in COPD significantly. 
 
  
Aim and Objectives 
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AIM AND OBJECTIVES 
 
1. To evaluate the cardiac abnormalities in stable COPD patients (GOLD 
Grades I, II, III and IV) to find out the coexisting cardiac comorbidities. 
 
2. To correlate the cardiac abnormalities with the severity of airway 
obstruction. 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
 COPD is associated with chronic inflammatory response to noxious 
stimulus. Usually it is a progressive disease. Cigarette smoking is the 
predominant risk factor for the development of COPD. Biomass fuel used for 
cooking in household is the predominant cause for COPD in non-smokers 
especially women. In industrialised countries, air pollution and indoor pollution 
cause COPD. Smoking not only causes respiratory diseases but can affect many 
systems. CAHD, aero-digestive tract malignancy, Thrombo-angiitisobliterans 
etc. are associated with smoking. Lung function declines with the continuation 
of smoking. Various studies suggest that there is a decline of 60ml/year in the 
FEV1 value in smokers whereas in non-smokers it is 30ml/year 6 . 
 
 
Fig. 2 - This graph depicts the continuous decline of more lung function in 
continuous smokers than intermittent and sustained quitters. 
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SMOKING INDEX  
 Smoking index is calculated as the product of number of cigarettes or 
bidis smoked per day and the duration of smoking habit in years. Thus smoking 
index takes into account both the quantity and the chronic nature of the 
problem. 
 The severity of smoking was measured based on Smoking Index as 
given in table.56 
Severity of Smoking Index 
Smoking Index Severity of smoking 
<100 Light Smokers 
100 – 300 Moderate Smokers 
>300 Heavy Smokers 
 
 
NATURAL HISTORY OF COPD18 
1. There is an increase in lung function with growth in childhood and 
adolescence.  
2. Events in foetal and childhood period can affect lung growth and 
development which reduces the maximally attained lung function. 
3.  After completion of growth of lung, lung function will remain constant 
for some time termed as   the “plateau phase”, after which lung function 
will decline at an accelerating rate as age increases.  
4. Smoking reduces this “plateau phase” duration and accelerates the rate 
of lung function loss. 
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5.  Early Smoking cessation could reduce the rate of lung function loss to 
that of a non-smoker.  
6. Patients typically present with symptoms when lung function declines 
below 50% of that in young adulthood. 
 
 
Fig 3 : Fletcher Peto curve of the natural history of COPD 
 
Diagnosis and grading of COPD  
 According to the Global Initiative for Obstructive Lung Disease, airflow 
obstruction is considered when there is a reduction of the post bronchodilator 
FEV1/FVC ratio below 70% and the percentage of the post bronchodilator 
FEV1 of the predicted normal FEV1 is used to grade the severity of COPD. 
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GOLD GRADING 
 The following table depicts the grading of severity of COPD according 
to the GOLD guidelines. 
  
 
 
Exacerbation of COPD60 
 GOLD states, “An exacerbation of COPD is an acute event 
characterized by a worsening of the patient’s respiratory symptoms that is 
beyond normal day to- day variations and leads to a change in medication.” 
 
COPD phenotypes60 
 Clinical phenotype is defined as: “a single or combination of disease 
attributes that describe differences between individuals with COPD as they 
relate to clinically meaningful outcomes (symptoms, exacerbations, response to 
therapy, rate of disease progression, or death)”. 
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 Many disease characteristics (i.e., phenotypic traits) had been proposed 
as potential COPD phenotypes, but only a few had been validated prospectively 
accordingly to this definition  
 
1. Alpha1-antitrypsin deficiency in which the specific gene/protein had 
been identified and specific therapy had been developed  
2. Upper lobe emphysema, with poor exercise tolerance after 
rehabilitation, in patients with severe airflow limitation, whose survival 
improves with lung volume reduction surgery, and  
3. Frequent exacerbations (two or more per year) that might benefit from 
anti-inflammatory therapy”. 
 
Following are the potential clinical COPD phenotypes that require validation. 
They are* 
1. “Disproportionate dyspnea” 
2. “Persistent systemic inflammation”, -- associated with increased 
mortality and exacerbation rate; 
3. “Chronic bronchitis”,  
4. Presence of chronic airway bacterial colonization 
5. Emphysema and its relation with pulmonary hyperinflation and lung 
cancer 
6. The mixed phenotype asthma/COPD and 
7. “Out-of proportion” pulmonary hypertension. 
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COMBINED ASSESSMENT OF COPD 
Symptoms 
 Less symptoms---- mMRC 0-1: CAT <10      patient A OR C 
 More symptoms – mMRC ≥2: CAT >10      patient B or D 
 
Airflow limitation 
 Low risk   -GOLD 1 OR 2         Patient A or B  
 High risk –GOLD 3 OR 4        Patient C or D 
 
Exacerbations 
 Low risk - ≤1 per year and no hospitalisations per year – patient A or B 
 High risk - ≥ 2 per year or ≥1 hospitalisation per year- Patient C or D 
 
 
Fig. 4 :  Combined Assessment of COPD  
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SPIROMETRY (ATS Guidelines) 
 Spirometry is a physiological test that measures how an individual 
inhales or exhales volumes of air as a function of time. 
 
Test procedure  
There are three distinct phases to the FVC manoeuvre, as follows:  
  1) Maximal inspiration;  
  2) A ‘‘blast’’ of exhalation; and   
  3) Continued complete exhalation to the end of test (EOT) 
 
 The patient was asked to take the deepest breath they can, and then 
exhale into the sensor as hard as possible, for as long as possible, preferably at 
least 6 seconds which was followed by a rapid inhalation (inspiration). 
 
 During the test, soft nose clips were used to prevent air escaping through 
the nose. Filter mouthpieces were used to prevent the spread of 
microorganisms. 
 
1. Before the test, the patient's age, gender, and race are recorded 
2. Height and weight are measured 
3. The patient should not have eaten heavily within three hours of the test 
4. He or she should be instructed to wear loose-fitting clothing over the 
chest and abdominal area. 
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Fig. 5 : Person doing spirometry 
 
5. The respiratory therapist or other testing personnel should explain and 
demonstrate the breathing manoeuvres to the patient. 
6. The patient should practice breathing into the mouthpiece until he or she 
is able to duplicate the manoeuvres successfully on two consecutive 
attempts. 
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Fig. 6 : ACCEPTABILITY CRITERIA 
    
 
 
 
Fig. 7 : REPRODUCIBILITY CRITERIA 
 
  
15 
 
REVERSIBILITY TESTING  
1. Stop Short-acting inhaled drugs (e.g. the βagonist albuterol/salbutamol 
or the anticholinergic agent ipratropium bromide) before 4 hours of 
testing.   
2. Stop the long-acting β-agonist bronchodilators (e.g. salmeterol or 
formoterol) and oral therapy with aminophylline or slow release β-
agonists 12 hours prior to the test. 
3. Avoid smoking for >1 hour prior to testing and throughout the duration 
of the test procedure. 
4. The subject has to do three acceptable tests of FEV1, FVC and PEF as 
described previously.  
5. Short acting bronchodilator(salbutamol) is then  administered.  
6. After 10 -15 minutes of salbutamol nebulization, another three  
acceptable tests are recorded. 
 
POSTBRONCHODILATOR REVERSIBILITY 
The percentage improvement in FEV1 can be calculated as follows: 
   
(Post bronchodilator FEV1 - Prebronchodilator FEV1) X 100 
Prebronchodilator FEV1 
 
Significant reversibility: 
 Increase in the post bronchodilator FEV1 more than 15 per cent of the 
pre-trial value or more than 200ml is considered as positive response. 
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CARDIOVASCULAR COMORBIDITY IN COPD 
 
 Coronary heart disease and COPD are sharing the common risk factor, 
i.e. smoking. Therefore it won’t be surprising that there will exist a strong 
epidemiological link between them. When there is decrease of 10%  in FEV1, 
cardiovascular mortality increases  by 28% and  non-fatal coronary events 
increases by 20%. 30  
 
 Wenjia Chen et al 31 did a study named “Risk of cardiovascular 
comorbidity in patients with chronic obstructive pulmonary disease: a 
systematic review and meta-analysis”. They analysed 18,176 unique references 
and included 29 datasets in the meta-analyses. They concluded “Compared 
with the non-COPD population, patients with COPD were more likely to be 
diagnosed with cardiovascular disease (odds ratio [OR] 2.46; 95% CI 2.02–
3.00; p<0.0001), including a two to five times higher risk of ischaemic heart 
disease, cardiac dysrhythmia, heart failure, diseases of the pulmonary 
circulation, and diseases of the arteries. Additionally, patients with COPD 
reported hypertension more often (OR 1.33, 95% CI 1.13–1.56; p=0.0007), 
diabetes (1.36, 1.21–1.53; p<0.0001], and ever smoking (4.25, 3.23–5.60; 
p<0.0001). The associations between COPD and these cardiovascular disease 
types and cardiovascular disease risk factors were consistent and valid across 
studies. Enrolment period, age, quality of data, and COPD diagnosis partly 
explained the heterogeneity.” 
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 Thus COPD patients are at more risk of CVD than non-COPD 
necessitating a routine cardiac work-up in all COPD patients.  
 
PULMONARY HYPERTENSION AND COPD 
 Barbara et al34 reviewed the different aspects of pulmonary hypertension 
associated with COPD. While elucidating the natural history of pulmonary 
hypertension in chronic obstructive pulmonary disease, emphasised 
“pulmonary hypertension progresses over time and its severity correlates with 
the severity of airflow limitation”. 
 
 Various factors contribute to the development of pulmonary 
hypertension in COPD. Among them, the most significant are pulmonary 
vasculature remodelling (shown in the picture) and pulmonary vasoconstriction 
in response to hypoxia. 
 
 
Fig. 8 : Vascular Changes 
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 Altered endothelial function and inhibition of NO result in  up-
regulation of the gene expression of  VEGF and increase in  cellular  
proliferation and vessel remodelling in pulmonary hypertensive states [32,33]. 
Similar changes are observed both  in patients with and  without COPD . From 
this it is clear that some other factors are also contributing to the development 
of pulmonary hypertension in COPD. It has been postulated that inflammation 
and cigarette-smoke products have direct effect on vessels. 
 
 
Fig 9 : Pathophysiology of pulmonary hypertension in COPD 
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IMPACT OF PH ON SURVIVAL OF COPD PATIENTS 
 The following graph depicts the impact of PH on survival in patients 
with advanced COPD. Oswald Mammosser et al stated” Patients with COPD 
with a mean pulmonary artery pressure (mPAP) of 25 mm Hg (dashed line) at 
the beginning of long-term oxygen therapy had a significantly (P = .001) 
shorter life expectancy than patients with an mPAP of < 25 mm Hg (solid 
line)” and also stated “Only long-term oxygen therapy has been shown to be 
beneficial, which stabilises PH in certain patients with COPD”.21 
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 PULMONARY ARTERY CATHETERIZATION   
  It is considered as the gold standard in the assessment of 
pulmonary hemodynamics. As it is an invasive procedure, its routine use in the 
evaluation of COPD is precluded. However, in patients in whom significant 
elevations are suspected or under evaluation for potential LVRS or transplant, 
its use is justifiable. Pulmonary hypertension (PH) is defined as an” increased 
mean pulmonary artery pressure >25 mmHg at rest as assessed by right heart 
catheterisation (RHC)”. 
 
PULMONARY HYPERTENSION AND COPD 
 1. In the article “Pulmonary hypertension in chronic obstructive 
pulmonary disease”   Barbera, Peinado, Santos concluded that most studies 
reported 30 -70% prevalence of PH in COPD and PH typically occurred in 
severe COPD patients (FEV1 value < 30% predicted) and who had hypoxemia. 
Severe PH (defined as mPAP > 40 mm Hg) was uncommon (1–3%) in  
COPD 34. 
 2. Vadim Fayngersh, Fotios Drakopanagiotakis, F. Dennis McCool, 
James R. Klinger did a study named  “ Pulmonary Hypertension in a Stable 
Community-Based COPD Population” in which they found that in 105 
individuals with demonstrable TR jet, 63(60%) had PH (>36mmhg). When cut-
off value for PH was increased to 40mmHg, still 49 (47%) persons had PH. 
They said “It was likely that some of the individuals in whom a jet could not be 
visualized also had PH” 35. 
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 3. SCHARF et al 36 reported a very high incidence of PH (91%) (mPpa 
more than 20mmHg). There was slow rate of progression of PH in COPD and  
mPpa was found to be  moderately elevated, even in patients with advanced 
disease. 
 
 4. In 1981, WEITZENBLUM et al. 37 showed in 175 patients with 
COPD, the incidence was 35% and also said “those with Ppa (20 mmHg) had a 
shorter survival than those whose Ppa was normal”. 
 
 5. Chaouat et al 38 in “Severe pulmonary hypertension and chronic 
obstructive pulmonary disease” with 998 severe COPD , the prevalence of 
severe PH (Ppa > 40 mm Hg) was 2.7%. But 50% of them had non-COPD 
etiologies to explain that. Thus the prevalence of severe PH is uncommon in 
COPD. 
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 6.  N.K. Gupta et al 39 in a study with 27/40 COPD of demonstrable TR 
jet in ECHO,63% had PH .The following table shows the  frequencies of 
PH(SPAP > 30 mmHg) in various COPD grades.  
 
 
 
 
 7. Similarly Barbera` and Blanco 40 also found high prevalence of PH in 
patients with advanced COPD and said “In milder forms PH might not be 
present at rest but may develop during exercise”. 
 
 8. Rabab et al 41 reported in their study about LV function in patients 
with or without PH comprising 36 copd and 12 matched control group, a 
prevalence of about 55.6% (20 COPD patients) regarding pulmonary 
hypertension [one mild (12.5%), 5 moderate (50%), 5 severe (55.6%), and 9 
very severe (100%)] with highly significant difference between mild and very 
severe COPD (P < 0.01).  
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LV FUNCTION AND COPD 
 9. In the above study authors said “Left ventricular diastolic function 
and global function were affected in COPD patients especially with progression 
of the disease. COPD patients with pulmonary hypertension were more liable 
to LV diastolic and global dysfunction than normal pulmonary pressure COPD 
patients”. And also concluded that  Left ventricular systolic function had  not 
shown any difference between patient and control groups 41. 
 
 10. Frans H. Rutten et al 42 found out that 50 elderly COPD  patients 
(20.5%, 95% CI 15.6–26.1) with stable chronic obstructive pulmonary disease 
had unrecognized heart failure  out of  those 244 enrolled in the study.  
 
 11. Gupta et al 39 in their study on role of ECHO in COPD concluded 
that LVDD was present in (19)47.5% of patients, out of which 16 had PH and 3 
did not have PH, various mechanisms might explain the presence of left 
ventricular diastolic dysfunction in COPD patients. 
 
 12. Lopez Sanchez et al 43 in their study on LV function in COPD 
reported a high prevalence of LVDD in stable severe COPD patients and 
concluded that “LVDD might be the reason for their lower exercise tolerance” 
and “Hypoxemia could have a concomitant role in their pathogenesis”. In a 
similar study, Laura Miranda et al 44 also reported such high prevalence of 
LVDD in severe stable COPD patients. 
 
24 
 
 13. In the study “ Left Ventricular Diastolic Dysfunction in Patients with 
COPD in the Presence and Absence of Elevated Pulmonary Arterial Pressure”, 
Georg-Christian Funk et al 45 reported occurrence of LVDD in COPD patients 
with normal PAP also. 
 
 
 
 14. Suchon´ et al. 46, found that ejection fraction, shortening fraction and 
lateral mitral annular peak systolic velocity (S wave) in COPD patients, were in 
the normal value range and did not differ significantly from control group. 
 
 15. Rabab et al 47 also concluded that LV systolic dysfunction was not 
found in the COPD subjects in the course of the disease. 
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 16. Burghuber et al 48 in his study states “in the absence of conditions 
primarily leading to left ventricular systolic function impairment (ischemic 
heart disease, systemic arterial hypertension, etc.), the derangement of systolic 
function in the course of COPD is rarely found”. 
 
 17.  A. Boussuges,et al 49,in his study stated”  LVDD was present when 
SPAPp >60mmHg as measured by impaired relaxation type  of LV 
dysfunction” 
 
 18.  A. Moustapha, et al 50 stated “LVDD was present in 6% of copd 
patients with SPAP<60mmHg”. 
  
RV FUNCTION IN COPD 
 Alpert JS 52, in his article on  Effect of right ventricular dysfunction on 
left ventricular function, states “Right ventricular dilatation and hypertrophy 
shift the interventricular septum leftward, thereby causing decreased left 
ventricular cavity size, contractility, compliance, and ejection fraction as well 
as increased left ventricular diastolic pressure.” This phenomenon is called as 
“the reverse Bernheim phenomenon,”or “ventricular interaction or ventricular 
interdependence”. 
 
 Omar A. Minai et al 53 concluded “ Most patients with COPD-associated 
PH have preserved RV contractility if studied during periods of clinical 
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stability, 38 and studies have demonstrated RV systolic failure only among 
patients in the acutely decompensated state”.  
 
TAPSE 
 Tricuspid annular plane systolic excursion (TAPSE):** 
 
 TAPSE  denotes the distance of systolic excursion of the Right Ventricle 
annular plane towards  apex . It is measured with the M-mode cursor passing 
through the tricuspid lateral annulus, using 4-chamber view.It represents how 
much the annulus displace longitudinally at peak systole.. 
 Views to evaluate right ventricle are  shown below.  
 
 
 
Fig. 10 :   4-chamber apical view 
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Fig. 11 : Apical – 4 – chamber view with focus on RV 
 
 
Fig. 12 : Subcostal view 
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  TAPSE  above 16 mm is considered as normal. It correlates well  
with various other techniques used to estimate global systolic function of 
right ventricle. 
 
 It is simple and relatively independent on optimal image quality 
and reproducible.  
 
 Disadvantages: It has been assumed that the displacement of a 
single segment would  be represententative of the function of whole right 
ventricle. It depends on the  angle at which it is estimated and also on the 
ventricular load. 
 
  TAPSE would be utilised routinely as a method of estimating RV 
function, keeping 16mm as cut-off value below which is considered 
abnormal. 
 
 TEI INDEX 54 
1. Tei index is being used to assess the global function of the right 
ventricle. This global myocardial performance index needs the 
measurements of both the tricuspid inflow and the right ventricular 
outflow by pulsed wave Doppler . Normal values are 0.28 ±0.04. 
2. More severe the right ventricular dysfunction, more abnormal the Tei 
index (0.59 – 1.27 in patients with PAH) 
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3. Tei index is  relatively less dependent on right ventricular load. It is 
representative of  global assessment  of right ventricular function 
independent of geometric assumptions .  
 
  It is calculated using the following formula: 
   MPI = (IVRT + IVCT)/ET 
  Where MPI = Myocardial performance index(Tei index) 
  IVRT = Isovolumetric relaxation time 
  IVCT = Isovolumetric contraction time 
     ET  =  Ejection time 
 
There are two methods to determine Tei index : 
 
1) The pulsed Doppler method:  
 For estimating Ejection Time, view adopted is parasternal short-axis 
view. It is done at the pulmonary valve level and  based on the pulsed – wave 
Doppler signal at the right ventricular outflow tract. 
 
 Isovolumic intervals are derived based on the pulsed-wave Doppler 
envelope of the tricuspid flow. We took these measurements from two cardiac 
cycles. So, we must choose beats with similar R-R intervals to measure MPI 
accurately.  
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Fig. 13 
 
 The tricuspid (valve) closure opening time (TCO) encompasses 
isovolumic contraction time, ejection time (ET), and isovolumic relaxation 
time. In the pulsed Doppler method, TCO can also be measured by the duration 
of the tricuspid regurgitation continuous-wave Doppler signal.rom the diagram, 
   MPI = (TCO - ET)/ET 
 
2) The pulsed tissue Doppler method: 
 In this method, based on the pulsed-wave Doppler  at the tricuspid level 
of the right ventricular free wall, all the times such as IVRT ,IVCT AND ET 
are measured  from a single heart-beat.  
 
 MPI would be unreliable when RA pressure was increased because of  
more rapid equilibration of pressures between the RV and RA, shortening the 
IVRT which would result in under-estimation of MPI. 
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 Normal value of Tei index using the pulsed Doppler method is  
0.28 ± 0.04.  
  
 
Fig. 14 : Schema of colour Doppler echocardiographic measurements 
 
A: Interval between the cessation of tricuspid in-flow and the start of the next 
tricuspid in-flow. 
 B: Interval between the R wave and the cessation of right ventricular (RV) out-
flow.  
C: Interval between the R wave and the start of tricuspid in-flow. 
 
 AcT: RV out-flow acceleration time (AcT) is the interval between the 
start of RV out-flow and peak velocity. Ejection time (ET) is the interval of RV 
out-flow, measured from the start to the end of the RV out-flow Doppler 
velocity profile below the baseline.  
 
 Isovolumetric contraction time (ICT) = (A – ET – IRT) 
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 Isovolumetric relaxation time (IRT) =(C – B). 
 
 The total ejection isovolume (TEI) index, which is a systolic and 
diastolic myocardial performance index, was calculated as (A – ET)/ET.   
 
 
Systolic Pulmonary Artery Pressure (SPAP) 
 SPAP can be estimated using Tricuspid regurgitant  velocity. 
 RVSP can be reliably derived  from peak TR jet velocity, using the 
simplified Bernoulli equation and combining this value with an estimate 
of the RA pressure  
    RVSP = 4(V) 2 + RA pressure,  
 Where V is the peak velocity (m/s) of the TR jet. 
 
 In the absence of a gradient across the pulmonary valve or RVOT, 
SPAP is equal to RVSP. In cases in which RVSP is elevated, obstruction 
at the level of the RVOT or pulmonic valve should be excluded. 
 
 Because velocity measurements are angle-dependent, it is better to 
obtain  TR signals from many windows and utilise high velocity  signal . 
it will be possible in most of  the patients. It is recommended that 
Doppler sweep speeds of 100 mm/s be used for all tracings. 
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1. Grading of pulmonary hypertension is as follows:61 
Grading of PHT SPAP 
Normal 18-25mmHg 
Mild 30 – 40 mmHg 
Moderate 40 - 70 mmHg 
Severe >70mmHg 
 
Doppler echocardiographic determination of systolic pulmonary artery 
pressure (SPAP).  
 
     Fig.15 
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     Fig.16 
1. A represents Tricuspid regurgitation signal that is not contrast 
enhanced and correctly measured at the peak velocity.  
 
2. B represents TR signal after contrast enhancement. Here, the clear 
envelope has been obscured by noise, and the reader erroneously 
estimated a gradient several points higher. As this example shows, 
it is critical that only well-defined borders be used for velocity 
measurement, as slight errors are magnified by the second-order 
relationship between velocity and derived pressure. 
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LV FUNCTION  
1. Left ventricular function was also assessed by using :      
a. EF (ejection fraction) = measures how much volume present at 
the end of diastole is ejected from Left Ventricle with each 
systole. Normal value is above  56%. 
b. E/A = diastolic filling of left ventricles usually classified 
initially on the basis of the peak mitral flow velocity of the early 
rapid filling wave (E), peak velocity of the late filling wave 
caused by atrial contraction (A). In normal subjects LV elastic 
recoil is vigorous because of normal myocardial relaxation, 
therefore more filling is completed during early diastolic, so left 
ventricular diastolic dysfunction (LVDD) is said to be present 
when E/A is <1.3 (age group 45–49 years), <1.2 (age group 50–
59 years), <1.0 (age group 60–69 years), and <0.8 (age group 
≥70 years)57. 
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ROLE OF ECHO IN EVALUATING COPD PATIENTS 54 
 In the presence of tricuspid regurgitation, an estimate of systolic 
pulmonary artery pressure could be provided by continuous-wave 
Doppler echocardiography. However, tricuspid regurgitation will be 
present in 24–66% of COPD patients, therefore limiting the possibility to 
estimate SPAP in some patients. But its use is strongly recommended for 
the assessment of pulmonary hypertension in COPD because of the 
information it provides on RV function despite limitations.  
 
 With echocardiography, cases of under- and over-estimations are 
not uncommon.it is not possible to measure mean pulmonary artery 
pressure directly using this method. Therefore, echocardiography can be 
considered as a tool for assessing the likelihood of PH. Transthoracic 
echocardiography can be useful for non-invasive screening of COPD 
patients at risk of PH. Patients showing signs suggestive of PH in 
echocardiography can be referred for a confirmatory RHC. 
  
Methodology 
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METHODOLOGY 
Subject selection 
     The present study approved by the institutional ethical committee was 
conducted in the department of pulmonary medicine,Kilpauk Medical College, 
Chennai over a period of 6 months from February 2015 to July 2015.  
 
 Collaborating department : Department of Cardiology,Kilpauk Medical 
College,Chennai. 
 
 Patients attending the pulmonary medicine out-patient department in 
Kilpauk Medical College Hospital (KMCH) and Govt.Thiruvotteeswarar 
Hospital of Thoracic Medicine (GTHTM) with symptoms suggestive of 
Chronic Obstructive Pulmonary Disease (COPD) were selected. 
 
 Informed written consent was obtained from all the patients prior to 
inclusion in the study  
 
 A patient was suspected to have COPD if he or she was above 40 years 
of age and had any one of the following as advocated by Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) guidelines, 201331. 
 
1. Dyspnoea 
  o Progressive 
  o Characteristically worse with exercise 
  o Persistent 
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2. Chronic cough 
  o May be intermittent 
  o May be unproductive 
3. Chronic sputum production 
  o Any pattern 
4. History of exposure to risk factors 
  o Tobacco smoke 
  o Smoke from home cooking and heating fuels 
  o Occupational dusts and chemicals 
5. Family history of COPD 
                     
INCLUSION CRITERIA 
1. Smokers 
2. Age above 40 years 
3. Newly diagnosed or Known COPD 
4. Clinically stable COPD(those who do not require change in regular 
medications for atleast 6 weeks)43 
5. Second hand smoke and Biomass fuel exposure 
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EXCLUSION CRITERIA 
1. Age less than 40 years 
2. Pre-existing other respiratory diseases like active pulmonary 
tuberculosis,  pulmonary tuberculosis sequalae, bronchiectasis, 
bronchial asthma, and lung malignancy. 
3. Known cardiac patient (valvular heart disease, IHD) or hypertensive 
4. COPD patients in acute exacerbation or history of  acute exacerbation of 
COPD within the last two months 
5. Those who are not willing for echo 
6. Those who are not able to perform Spirometry.  
 
 Among the patients attending pulmonology OPD, those who had been 
suspected of having COPD and satisfied the inclusion  and exclusion criteria 
were subjected first to sputum AFB smear and chest x-ray to rule out active 
PTB.  
 
 Then spirometry was done as per the ATS guidelines. A post-
bronchodilator forced expiratory volume in one second (FEV1)/forced vital 
capacity (FVC) less than 0.7 confirms the presence of airflow limitation. They 
were then subjected to haemoglobin, total count, differential count, ESR, blood 
sugar, urea and serum creatinine, cholesterol and ECG. Spirometry was done 
using Easyware 2 which is a computerised portable spirometer SN02134, 7.1 
version. 
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Fig.17 : Computerised spirometer - EASYWARE 2 
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Grading of severity of COPD was done according to GOLD guidelines. 
 GOLD Classification of Severity of Airflow Limitation in COPD, Based 
on Post-Bronchodilator FEV1** 
 
In Patients with FEV1/FVC < 0.70 
GOLD 1   Mild     FEV1 ≥ 80% predicted 
GOLD 2   Moderate    50% ≤ FEV1 < 80% predicted 
GOLD 3  Severe   30% ≤ FEV1 < 50% predicted 
GOLD 4  Very Severe  FEV1 < 30% predicted 
 
 All patients who had been enrolled in our study were subjected to 
resting two-dimension transthoracic Doppler echocardiography in the 
cardiology department of Kilpauk Medical College and hospital by expert 
cardiologists. The machine used was MyLabView ECHO machine system 
with a multifrequency probe with a range of 2–4.3 MHz.Both 2D and M-
Mode studies were done. Views adopted were apical 4-chamber view, 
subcostal view and RV focussed apical 4-chamber view. 
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Fig.18 : ESOATE My Lab FIVE ECHO MACHINE 
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Fig 19 : ESOATE My Lab FIVE ECHO MACHINE  
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 Assessment of the pericardium, valves and function, left atrial, left 
ventricular, right atrial and right ventricular size and cardiac function was 
done. Tricuspid regurgitant flow had been identified by colour flow Doppler 
technique. By continuous wave Doppler without the use of intravenous 
contrast, maximal Tricuspid regurgitant flow was observed… 
 
 We estimated the Right ventricular systolic pressure as per the modified 
Bernoulli equation. It had been considered to be equal to the SPAP (systolic 
pulmonary artery pressure) when there was absence of right ventricular 
outflow obstruction. 
 
SPAP (mmHg) = RVSP = TTPG +RAP 
Where RVSP = right ventricular systolic pressure, 
TTPG = trans-tricuspid pressure gradient and  
RAP = right atrial pressure (RAP),  
 
 Where trans-tricuspid gradient is 4v2 (v = peak velocity of tricuspid 
regurgitation, m/s). 
 
 We had taken a fixed value of 10 mmHg as right atrial pressure.   
 
 Pulmonary hypertension (PH) was said to be present when SPAP ≥ 30 
mmHg. This value was chosen according to the definition of pulmonary 
hypertension. PH was classified into mild, moderate, and severe category as 
SPAP 30–40, 40–60, >60 mmHg, respectively. 
45 
 
 
 
 Right ventricular systolic function was assessed by TAPSE (Tricuspid 
Annular Plane Systolic Excursion) and its global function was assessed by Tei 
index. 
 
 TAPSE was considered abnormal when it was less than 16mm 
 
Fig. 20  
 
 
Tei index was calculated using the following formula: 
  • MPI = (IVRT + IVCT)/ET 
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 Isovolumetric contraction time (IVCT) = (A – ET – IRT) 
 Isovolumetric relaxation time (IVRT) =(C – B). 
 
 The total ejection isovolume (TEI) index, which is a systolic and 
diastolic myocardial performance index, was calculated as (A – ET)/ET.   
 
 Normal mean range of Tei index is 0.28+/-0.04 
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We assessed the Left ventricular function by using the following 
parameters: 
 
 EF (ejection fraction) = measure of how much end-diastolic value  is 
ejected from LV with each contraction (56%–78%). 
 
 E/A = diastolic filling of left ventricles usually classified initially on the 
basis of the peak mitral flow velocity of the early rapid  filling wave (E),  
peak velocity of the late filling wave caused by atrial contraction (A). In 
normal subjects LV elastic recoil is  vigorous because of normal myocardial 
relaxation, therefore more filling is completed during early diastolic, so left 
ventricular diastolic dysfunction (LVDD) is said to be present when  
 
 E/A is  <1.3 (age group 45–49 years), 
    <1.2 (age group 50–59 years),  
   <1.0 (age group 60–69 years), and  
   <0.8 (age group ≥70 years). [13] 
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Study Design       :   Cross-Sectional Observational Study 
 
Place of Study :   Kilpauk Medical College and  
    GTHTM, Otteri. 
 
Duration of Study : 6 months(from Feb 2015 to July 2015) 
 
Sample Size      : 100 
Sampling  :    Consecutive COPD patients attending OPD   
 
 All data collected were analysed by SPSS version-17 for mean, 
SD, chi-square test and Pearson Correlation Test.  
 
  
Results 
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RESULTS 
PATIENT CHARACTERISTICS  
1.GENDER DISTRIBUTION 
 A total of 100 COPD patients who fulfilled the inclusion criteria were 
included in the study after obtaining informed consent. Of the 100 patients, 89 
were males and 11 were females. Thus males accounted for 89% of our study 
population while females accounted for 11%. 
 
Table 1 : Gender Distribution 
GENDER NO. OF PATIENTS 
MALE 89 
FEMALE 11 
TOTAL 100 
 
 
Fig 21 : Gender distribution 
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2.AGE DISTRIBUTION 
 Age group of our study population was in the range of 42 to 86 years. 
The mean age of the study population was 59.31 with the standard deviation of 
9.230. The number of patients in the age group 40-50,51-60,61-70,71-80,and 
>80 years were 21(21%),32(32% ),42(42%) ,3 (3% ) and 2 (2% ) respectively. 
 
Table 2 : Age Distribution 
AGE (years) MALE FEMALE TOTAL 
40-50 17 4 21 
50-60 27 5 32 
60-70 40 2 42 
70-80 3 0 3 
>80 2 0 2 
TOTAL 89 11 100 
      
 
Fig.22 :  Age distribution 
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3.SMOKING STATUS 
 All the 11 females in our study population were non-smokers. Among 
the 89 males, 18 were light smokers, 47 were moderate smokers, and 24 were 
heavy smokers. The smoking index of our study population ranged from 0 to 
700 with a mean value of 226.08. 
 
Table 3 : Smoking Index 
 
GENDER NON SMOKER <100 100-300 >300 TOTAL 
MALE 0 18 47 24 89 
FEMALE 11 0 0 0 11 
      
 
Fig 23 : Smoking status of study population 
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4.SMOKING STATUS AND GOLD COPD GRADE 
 Among GOLD 1 COPD patients, majority are light smokers 66.6%   
 In GOLD 2 COPD  patients ,majority are  moderate smokers 64.52% 
 In GOLD 3COPD majority are moderate smokers 53.85%  
 In GOLD 4 COPD, majority are heavy smokers(61.11%). 
 
 
Table 4 : Smoking severity and GOLD-COPD Grade 
SEVERITY 
OF 
SMOKING 
COPD-GOLD GRADING 
GOLD 1 GOLD 2 GOLD 3 GOLD 4 TOTAL 
HEAVY 0 3 10 11 24 
MODERATE 4 20 21 2 47 
MILD 8 8 1 1 18 
NON 
SMOKER 0 0 7 4 11 
TOTAL 12 31 39 18 100 
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Fig.24 :  Smoking severity and GOLD-COPD Grade 
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5.DEGREE OF AIRFLOW LIMITATION 
 Among females 7(7%)  and 4(4%) had severe and very severe COPD 
and none were in  mild or moderate COPD whereas among males, the number 
of mild, moderate, severe and very severe COPD were 12 (12%), 31(31%),  
32(32%) and 14(14%) respectively. The mean FEV1% of the study population 
was 48.17% 
 
Table 5 : Degree of Airflow Limitation 
 
GENDER GOLD1 GOLD II GOLD III GOLD IV TOTAL 
FEMALE   7 4 11 
MALE 12 31 32 14 89 
TOTAL 12 31 39 18 100 
 
 
       
Fig.25 : COPD severity 
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6.AGE-WISE DISTRIBUTION OF GRADES OF COPD  
 Among the 21 patients of 40-50 years age group, the number of mild, 
moderate, severe and very severe COPD were 10(47.61%),2(9.52%),6(28.57%) 
and 3(14.28%) respectively.in the 32 patients of 51-60years age group, the 
number of mild, moderate, severe and very severe COPD were 
1(3.125%),14(43.75%),11(34.375%)and 6(18.75%) respectively. among the 42 
patients in the 61-70 year age group the number of mild, moderate, severe and 
very severe COPD were 1(2.38%), 14(33.33%), 19(45.23%) and 8(19.04%) 
respectively. Among 71-80 year age group, 33.33% each had moderate, severe, 
and very severe COPD. 2 patients with age above 80 years had severe COPD. 
 
Table 6 : Age-Wise Distribution of Grades of COPD 
AGE 
GROUP GOLD I GOLD II GOLD III GOLD IV TOTAL 
40-50 10 2 6 3 21 
51-60 1 14 11 6 32 
61-70 1 14 19 8 42 
71-80  1 1 1 3 
>80   2  2 
 12 31 39 18 100 
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Fig. 26 :  Smoking severity and COPD severity 
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7.COPD-GOLD GRADE AND PULMONARY HYPERTENSION 
 Out of the 100 patients, 54(54%) had Pulmonary hypertension of which 
35(64.81%) had mild and 19 (35.18%) had moderate pulmonary hypertension. 
No one had severe pulmonary hypertension. 
 
 Among the 12 patients of GOLD I, 2 (16.66%) had PHT (mild PHT).  
Among the total 31 GOLD II patients, 8 (25.80%) had PHT (mild PHT).  
Among the total 39 GOLD III, 31(79.48%) had PHT of which 19 (61.29%) 
were  of mild PHT and 12 (38.70%) were of moderate PHT.  
 
 Out of the 18 GOLD IV, 13 (72.22%) had PHT of which 6(46.15%) 
were of mild  PHT and 7(53.84%) were of moderate PHT. 
 
Table 7 : COPD-Gold Grade and Pulmonary Hypertension 
GOLD-COPD 
GRADE 
SEVERITY OF PHT 
NORMAL MILD MODERATE TOTAL 
I 10 2 0 12 
II 23 8 0 31 
III 8 19 12 39 
IV 5 6 7 18 
TOTAL 46 35 19 100 
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Fig.27 : Correlation between COPD severity and PHT 
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8.COPD-GRADE AND TAPSE 
 All the patients in the study population had TAPSE in the normal mean 
range indicating no RV systolic dysfunction The Mean  TAPSE  of GOLD I, 
GOLD II, GOLD III, GOLD IV COPD grades  were 24,36,25,28mm 
respectively. 
Table : 8  COPD Grade and TAPSE 
 
GOLD GRADES MEAN OF TAPSE (mm) 
GOLD I 24 
GOLD II 36 
GOLD III 25 
GOLD IV 28 
 
 
Fig.28 :  COPD severity and TAPSE 
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9.COPD-GOLD GRADE AND TEI INDEX 
 In the 100 study subjects, 41(41%) had normal Tei index and 59(59%) 
had abnormal Tei index i.e. out of the normal mean range of Tei index. The 
number of people with abnormal TEI index in mild, moderate, severe and very 
severe COPD were 3(25%),12(38.70%),30(76.92%) and 14(77.77%) 
respectively. 
Table 9 : COPD Gold Grade and TEI Index 
GOLD-COPD 
STAGING 
TEI INDEX 
NORMAL ABNORMAL TOTAL 
I 9 3 12 
II 19 12 31 
III 9 30 39 
IV 4 14 18 
TOTAL 41 59 100 
 
 
Fig. 29 : COPD severity and Tei index 
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10.PHT AND TEI INDEX 
 Among the 48 patients with normal PHT, 8 (17.39%) had abnormal Tei 
index, whereas of the 35 patients with mild PHT, 32 (91.42%) had abnormal 
Tei index and all the 19 (100%) patients with moderate PHT had abnormal Tei 
index. 
Table 10 : Severity of PHT 
SEVERITY OF 
PHT 
TEI INDEX 
NORMAL ABNORMAL TOTAL 
NORMAL 38 8 46 
MILD 3 32 35 
MODERATE 0 19 19 
TOTAL 41 59 100 
 
 
Fig.30 : PHT  and Tei index 
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11.COPD AND EF 
 Out of the 100 COPD patients 5% had ejection fraction below 55% 
indicating LV systolic dysfunction.95% had normal ejection fraction. The 
mean ejection fraction of the study population was 63.75%. 
 
Table 11 : COPD and Ejection Fraction 
 
EJECTION FRACTION NO.OF.PATIENTS 
NORMAL 95 
ABNORMAL 5 
TOTAL 100 
 
 
Fig.31 : COPD  and Ejection fraction 
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12.COPD-GOLD GRADE AND EJECTION FRACTION 
 The mean Ejection fraction of mild, moderate, severe, and very severe 
COPD were 69.58, 63.90, 62.78, and 61.72 respectively. 
 
Table :12. Gold COPD Staging and Ejection Fraction 
 
 
Fig.32 :  COPD severity and ejection fraction 
GOLD I GOLD II GOLD III GOLD IV
EJECTION FRACTION % 69.58 63.9 62.76 61.72
69.58
63.9
62.76
61.72
56
58
60
62
64
66
68
70
72
M
EA
N
 E
F
COPD SEVERITY
EJECTION FRACTION %
GOLD-COPD 
STAGING 
EJECTION FRACTION (%) 
MAXIMUM MINIMUM MEAN 
I 73 60 69.58 
II 71 56 63.90 
III 74 25 62.76 
IV 72 36 61.72 
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13.COPD-GOLD GRADE AND LVDD 
 Of the 100 COPD study subjects, 73(73%) had no LV dysfunction and 
27(27%) had LV dysfunction. Out of the 27 patients with LV dysfunction, 
21(77.77%) had grade I LV Diastolic dysfunction, 4(14.81%) had grade II 
LVDD and 2(7%) had grade III LVDD. The number of patients with LVDD in 
mild, moderate, severe and very severe COPD were 2/12(16.66%), 
6/31(19.35%), 10/39(33.33%) and 9/18 (50%) respectively. 
 
Table 13 : LV DIASTOLIC DYSFUNCTION 
 
GOLD 
GRADE 
LV DIASTOLIC DYSFUNCTION 
TOTAL 
D0 D1 D2 D3 
I 10 2 0 0 12 
II 25 6 0 0 31 
III 29 7 1 2 39 
IV 9 6 3 0 18 
TOTAL 73 21 4 2 100 
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Fig. 33 : Correlation between COPD severity and LVDD 
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14.PHT AND LVDD 
 The number of patients with LVDD in patients with mild and 
moderate PHT were, 11/35(31.42%) and 8/19 (42.10%) respectively 
 
Table 14 : PHT & LVDD 
 
SEVERITY 
OF PHT 
GRADING OF LVDD  
D0 D1 D2 D3 D4 TOTAL 
NORMAL 39 5 1 1 0 46 
MILD 24 11 0 0 0 35 
MODERATE 10 5 3 0 1 19 
TOTAL 73 21 4 1 1 100 
 
 
Fig. 34 : Correlation between PHT & LVDD 
  
Discussion 
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DISCUSSION 
 
 
PATIENT CHARACTERISTICS 
 
1) AGE DISTRIBUTION 
1. Age group of our study population ranged from 42 to 86 years. 
2. The mean age of the study population was 59.31 with the standard 
deviation of          9.230 (59.31±9.230).  
3. The number of patients in the age group of 40-50,51-60,61-70,71-80,and 
>80 years were 21,32,42 ,3  and 2  respectively. 
4. Most of the patients in our study belonged to 50 – 70 years (74%) 
5. Mean age of our study population was 59.31±9.23 
 
     Comparison between our study and other studies 
STUDY MEAN AGE OF STUDY POPULATION 
Our study 59.31 ± 9.23 
George Christian et al 59.1 ± 1.7 
Rabab et al 55.1 ± 7.3 
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1. Mean age of male and female of our study population was similar to that 
in study by N.K.jain et al.  
 
STUDIES MALE FEMALE 
Our study 59.77+/- 9.41 55.54 +/- 6.8 
N.K. Jain et al 61.57+/- ±10.37 58.34+/- 9.99 
 
 Most females with COPD were younger than males indicating that 
females develop COPD early than males. This finding correlated with the study 
by N.K.Jain et al 
 
 This could be attributable to the biomass smoke exposure which begins 
early in females who start cooking using wood stoves at a very early age and 
also, sleep and eat in the same room where they cook. 
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2) GENDER DISTRIBUTION 
1. In our study, out of 100 patients, 89 were males and 11 were females. 
Thus males accounted for 89% of our study population while females 
accounted for 11%. 
2. In the past, most studies showed that COPD prevalence was high among 
men than women. This is reflected in our study also. 
3. Due to the increase in smoking habit in females, now studies report 
increasing prevalence of COPD among females.  
4. When compared to the gender distribution in the study by N.K.Jain et al, 
the percent of females in our study was less. Because they enrolled more 
females to study the difference in COPD character in relation to gender. 
 
Comparison between our study and other different studies 
STUDY MALE (%) FEMALE (%) 
Our study 89 11 
Rabab et al 83.3 16.7 
Lopez et al 87.5 12.5 
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3) SMOKING INDEX AND COPD GRADE 
1. Majority of our study subjects were moderate smokers (47%). 
2. Among GOLD I COPD patients, majority were light smokers (66.6%),  
3. Among  GOLD II and III COPD, majority were  moderate smokers 
(64.52%) and  (53.85% )   
1. Among GOLD IV COPD, majority were heavy smokers (61.11%). 
2. Thus, as smoking severity was increased, COPD severity also increased.   
3. Females  in our study had the mean FEV1 of 35.72% 
4. Among Males, light smokers had mean FEV1 of 69.5%, moderate 
smokers had meanFEV1 of 50.46%, and heavy smokers had mean 
FEV1 of 33.33%.It clearly indicated that as smoking increased FEV1 
decreased. There was a strong negative correlation in our study 
between FEV1 and Smoking Index (r -0.406). 
5. Cigarette smokers had a high annual rate of decline in FEV1 of about 50 
-60 mL, which was nearly double the average value of 30mL 
annually present in non-smokers. (Crofton 629 ) 
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4) SEVERITY OF COPD  
1. In our study majority of men were having moderate and severe COPD. 
Whereas females had severe and very severe COPD.  
2. Women were more susceptible to lung injury from smoking than men as 
they showed more lung function reduction in association with lower 
total exposure and they predominate among individuals with early onset 
of COPD and never-smokers with COPD.16 
3. In GOLD I COPD, 83% of patients were in the 40-50years age group. 
4. In GOLD II COPD,45% were in the51-60years age group 
5. In GOLD III COPD,48.75% were in the 61-70 years age group 
6. In GOLD IV COPD, 44.44% were in 61-70years age group. 
7. Thus, with advancing age, severity of COPD is increased.  
8. There was a significant correlation between severity of copd and age of 
the patients(p = 0.000) 
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5) COPD AND PULMONARY HYPERTENSION 
1. In our study, Out of the 100 patients, 54(54%) had Pulmonary 
hypertension.  
2. Vadim Fayngersh et al study named  “ Pulmonary Hypertension in a 
Stable Community-Based COPD Population” in which they found that 
in 105 individuals with demonstrable TR jet, 63(60%) had PH  
3. Rabab et al, in their study “LV function in patients with or without PH” 
comprising 36 COPD and 12 matched control group, reported 55.6% 
prevalence of pulmonary hypertension. 
4. N.K.Gupta et al reported a prevalence of 63% pulmonary hypertension. 
5. Scharf et al reported a very high incidence of 91% PH whereas 
weitzenblum reported 35% PH in their study. 
6. This variable prevalence of PH in different studies has been attributed to 
the different cut-off value for PH and difference in the population 
characteristics of study subjects. 
7. In our study, as the severity of COPD increased, the frequency of PH 
also increased, from 25% in GOLD I COPD to 72.22% in GOLD IV 
COPD.   
8. No one in our study had severe pulmonary hypertension. 
9. In the article “Pulmonary hypertension in chronic obstructive pulmonary 
disease” by Barbera et al concluded that Severe PH (defined as mPAP > 
40 mm Hg) was uncommon (1–3%) in COPD. 
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10. In the study “Severe pulmonary hypertension and chronic obstructive 
pulmonary disease” with 998 COPD patients (median FEV1 = 50% of 
predicted), Chaouat et al reported that the prevalence of severe PH (PPA 
> 40 mm Hg) was 2.7%. But 50% of them had non-COPD etiologies to 
explain that. Thus the prevalence of severe PH is uncommon in COPD. 
 
Frequency of PH in various studies 
STUDY FREQUENCY OF PH (%) 
Our study 54 
Vadim et al 60 
Rabab et al 55.6 
N.K.Gupta et al 63 
Scharf et al 91 
Weitzenblum et al 35 
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6) COPD AND TAPSE 
1. TAPSE value of all our patients was above 16mm indicating no RV 
systolic dysfunction in our study. 
2. In patients with COPD, because of the mild elevations in afterload and 
the slow disease progression, the right ventricle has a chance to adapt 
with hypertrophy, and RV systolic failure may not occur in the absence 
of comorbidities when patients are in a long-term stable state. 
3. Most patients with COPD-associated PH had preserved RV contractility 
if studied during periods of clinical stability,38 and studies had 
demonstrated RV systolic failure only among patients in the acutely 
decompensated state.38 
4. Since all our patients were clinically stable COPD patients, they had 
preserved RV systolic function. 
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7) COPD AND TEI INDEX 
5. In the 100 study subjects, 41(41%) had normal Tei index and 59(59%) 
had abnormal Tei index.   
6. The number of people with abnormal TEI index in mild, moderate, 
severe and very severe COPD were 3(25%), 12(38.70%), 30(76.92%) 
and 14(77.77%) respectively. 
7. Thus the Prevalence of abnormal Tei index had a linear relationship 
with severity of COPD 
8. In our study there was a statistically significant correlation between Tei 
index and severity of COPD. 
9. In the 35 patients with mild PHT, 32 (91.42%) had abnormal Tei index 
and all the 19 (100%) patients with moderate PHT had abnormal Tei 
index. 
10. There was a significant correlation between Tei index and pulmonary 
hypertension in our study (P value 0.000) and also there was a strong 
positive correlation between them(r = 0.721).  
11. If the severity of pulmonary hypertension increased, there occurred an 
increase in the Tei index value suggesting RV global function 
impairment...  
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8) COPD AND LV FUNCTION 
1. In our study, out of the 100 COPD patients, 5% had ejection fraction 
below 55% indicating LV systolic dysfunction.95% had normal ejection 
fraction. The mean ejection fraction of the study population was 
63.75%. 
2. It was an incidental finding (IHD) found out during the 
echocardiographic examination of the study subjects. 
3. Unless there was an inherent IHD, LV systolic function was usually 
preserved in COPD Patients. 
4. Prevalence rates of left ventricular systolic dysfunction in patients with 
COPD ranged from 4 to 32% and are usually associated with 
concomitant coronary heart disease.20–23.the prevalence of LV systolic 
dysfunction was 5% in our study and all were due to coronary artery 
disease. 
5. Martha Lopez et al reported a high prevalence (90%) of LV diastolic 
dysfunction in stable severe COPD 
6. In our study, the prevalence of LV diastolic dysfunction in severe and 
very severe stable COPD was lower (33.33%)  
7. Past  Studies indicated that the prevalence of mild LVDD in people 
older than 65 years with a normal LVEF is 21.7% and this increased to 
27% in those older than 70 [17,18]. 
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8. In the study by Martha Lopez et al, mean age of study population was 
65+/- 7, whereas in our study the mean age is 59.31+/-9.23.many of the 
patients were older and all of them were heavy smokers and continued 
smoking till the study had been undertaken.  
9. Because of these reasons the incidence of LVDD was high in that study. 
10. Similar to the study by Lopez et al, there was no correlation between 
SPAP and degree of LVDD in our study. 
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SUMMARY 
 
In our study with 100 stable COPD patients, we found that 
1. Prevalence of COPD in female was lower than males. 
2. When compared to males, female were somewhat younger in age 
because females develop COPD early due to their increased 
susceptibility to lung injury by smoke exposure. 
3. There was a strong negative correlation between smoking index and 
FEV1%  
4. Frequency of pulmonary hypertension increased linearly  with the 
severity of COPD 
5. There was a significant correlation between severity of COPD and 
pulmonary hypertension in our study. 
6. Severe pulmonary hypertension was uncommon in stable COPD 
patients. 
7. Stable COPD patients with pulmonary hypertension had preserved RV 
contractility (TAPSE) when they were in stable state for a long time and 
in the absence of other comorbidities.  
8. COPD patients had abnormal Tei index. 
9. There was statistically significant correlation between Tei index and 
severity of COPD  
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11. There was a strong positive correlation between Tei index and 
pulmonary hypertension. 
12. As the systolic pulmonary artery pressure was increased, Tei index 
value increased above the normal. 
13. Unless there was a coexisting ischaemic heart disease, COPD patients 
had normal LV systolic function  
14. There was no correlation with degree of LV dysfunction and SPAP. 
 
 
  
Conclusion 
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CONCLUSION 
 
1. Among the extra-pulmonary systemic co-morbidities, cardiac 
manifestations are one of the most common comorbidities. 
2. Since there is an anatomical and functional relation between lungs and 
heart, any dysfunction that impacts any one of the organs will have 
consequences in the other organ. 
3. So, all COPD patients have to be evaluated for the presence of cardiac 
abnormalities. 
4. Similarly, all patients with cardiovascular diseases should be evaluated 
for the presence of concomitant airflow obstruction. 
5. Even though COPD is a progressive disease with high mortality rate, 
early diagnosis of coexisting cardiac abnormalities will reduce the 
morbidity and mortality in COPD patients. 
 
  
Limitations 
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LIMITATIONS 
 
1. Sample size is small. Needs a study with large number of subjects 
2. No control groups are included in this study  
3. Smoking is a risk factor for both the cardiovascular diseases and COPD. 
Hence studies with “smokers without COPD” as matched control will 
bring out the real magnitude of cardiac abnormalities that would be 
contributed by COPD itself.  
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 ABBREVIATIONS 
 
 
COPD  - Chronic obstructive pulmonary disease 
mMRC - Modified Medical Research Council 
FEV1  - Forced expiratory volume in 1 second 
TAPSE - Tricuspid Annular Plane Systolic Excursion 
LVDD - Left Ventricular diastolic dysfuction 
MPI  - Myocardial Performance Index 
EF  - Ejection Fraction 
CVD  - Cardiovascular disease 
CAHD -          Coronary Artery Heart Disease 
CAT  - COPD Assessment Test 
S.D  - Standard deviation 
ATS  - American Thoracic  Society 
GOLD - Global initiaitive for obstructive lung diseases 
PH/PHT  - Pulmonary Hypertension 
SPAP  - Systolic Pulmonary Artery Pressure 
PAP  - Pulmonary Artery Pressure 
mPpa  - Mean Pulmonary Artery Pressure 
LV  - Left Ventricle 
 
 
 
  
PROFORMA 
 
Demographic data                                                
 
Name :                                                                    Address : 
 
Age/ Sex : 
 
Height,Weight, BMI:                                             Mobile no: 
 
Socio-economic  status :                                      Landline no: 
 
Marital status: Married/Unmarried 
 
CLINICAL DATA 
 
Symptoms with duration : 
 
       a.Cough with expectoration; 
 
       b.fever; 
 
       c.breathlessness on exertion 
 
       d.Hemoptysis;  
 
       e.chest pain 
 
       f. LOA/LOW  
 
       .others 
 
 
 
Co-morbid illness : 
 
              1.DM/HT/Heart diseases/Epilepsy/Others 
 
    
Alcohol: Yes/No     Duration: 
 
Smoking:Yes/No     Duration: 
  
 
 
O/E: 
 
    
 
 
VITALS 
     
    Spo2 : 
 
    PR    : 
 
    RR   : 
 
    BP    : 
 
 
INVESTIGATIONS : 
XRAY CHEST 
SPUTUM AFB SMEAR 
HEMOGRAM  
PFT 
ECG 
ECHO 
. 
  
MASTER CHART 
S. 
No 
NAME AGE SEX S.I 
FEV1 
% 
GOLD  
SPAP 
mmHg 
PHT  
TAPSE 
mm 
TEI 
LV 
DD 
EF% 
1 DEVARAJ 64 M 480 53 O 22.8 N 22.4 0.22 D0 67 
2 DEVAN 65 M 180 55 O 21.2 N 22.8 0.22 D0 59 
3 THANTHONI 54 M 280 34 S 19 N 16.9 0.23 D3 43 
4 LATHA 45 F   44 S 19 N 23.9 0.23 D0 71 
5 JAGADEESAN 47 M 120 82 M 19 N 20.4 0.24 D0 71 
6 RAGHURAM 75 M 280 53 O 25 N 22.9 0.24 D0 59 
7 VINCENT 54 M 140 54 O 19.9 N 23 0.24 D0 68 
8 SHANMUGAM 63 M 240 55 O 24 N 23.4 0.24 D0 66 
9 RAJENDRAN 63 M 80 65 O 18.9 N 19.4 0.25 D0 61 
10 MURUGAN 48 M 90 90 M 20.2 N 20.3 0.25 D0 72 
11 SELVAM 48 M 110 93 M 22.4 N 22.8 0.25 D0 71 
12 EKAMBARAN 56 M 80 54 O 19.6 N 23.5 0.25 D0 67 
13 NEEDHI 42 M 100 46 S 19.5 N 17 0.26 D0 74 
14 PADMA 50 F   34 S 22 N 24.2 0.26 D0 70 
15 VENKATESAN 45 M 48 81 M 19.9 N 17.1 0.27 D0 72 
16 MOHAN 42 M 60 82 M 24 N 24 0.27 D0 72 
17 DILLIKUMAR 56 M 280 57 O 24 N 24.2 0.27 D0 68 
18 JOE 64 M 80 61 O 25 N 20.7 0.28 D0 65 
19 NATARAJ 63 M 80 67 O 24.9 N 22 0.28 D0 66 
20 SABARINATHAN 45 M 72 86 M 22 N 23 0.28 D0 70 
21 SUMATHI 50 F   47 S 23 N 23.4 0.28 D0 72 
22 JAYAPAL 56 M 420 54 O 19 N 23.9 0.28 D0 66 
23 CHANDRAN 58 M 300 55 O 23 N 20.2 0.29 D0 68 
24 CHELLAPPA 56 M 300 55 O 25 N 23.7 0.29 D0 68 
25 GOVINDASAMY 60 M 150 56 O 20.7 N 19.6 0.3 D0 63 
26 MANOHAR 50 M 80 87 M 23.1 N 21.5 0.3 D1 68 
27 CHANDRAN 65 M 260 52 O 23 N 24.3 0.3 D0 59 
28 DEVADOSS 49 M 150 80 M 23.1 N 20.3 0.31 D0 68 
29 PANNEERSELVAM 60 M 80 25 V 19.9 N 21.7 0.31 D0 66 
30 KALIVARATHAN 42 M 75 81 M 22 N 22.3 0.31 D0 73 
31 BABU 67 M 200 29 v 20.3 N 23.8 0.31 D0 61 
32 KUMAR 45 M 90 79 O 20 N 24 0.31 D0 71 
33 DURAISAMY 61 M 130 54 O 18 N 19.4 0.32 D0 66 
34 KARUPPAN 51 M 300 54 O 22 N 22.8 0.32 D0 65 
35 BALASUNDARAM 48 M 400 49 S 18.7 N  23.6 0.32 D0 72 
36 RAVEENDRAN 56 M 380 31 S 25 N 17 0.33 D2 64 
37 EBINESAR 51 M 380 28 V 23 N 22.6 0.34 D0 65 
38 BALAN 65 M 300 29 V 23 N  17.5 0.35 D1 66 
39 THIRUVENGADAM 70 M 360 36 S 35.9 MILD 18.9 0.35 D0 59 
40 MANICKAM 65 M 180 39 S 37.2 MILD 19.9 0.35 D0 63 
41 MANI.R.K 64 M 520 28 V 35.8 MILD 23.1 0.35 D1 65 
42 CHINNAPPAN 70 M 490 24 V 35.4 MILD 16.5 0.36 D0 56 
43 NITHYANANDHAM 53 M 200 72 O 35.5 MILD 17 0.36 D0 65 
44 VENUGOPAL 65 M 450 25 V  36.2 MILD 17 0.36 D1 61 
45 RANI 55 F   46 S 37.9 MILD 17.2 0.36 D0 68 
46 RANGASAMY 60 M 700 52 O 36.9 MILD 18 0.36 D0 60 
47 RAMALINGAM 70 M 120 40 S 36.2 MILD 18 0.36 D1 69 
48 MOINUDEEN SHERIF 45 M 500 25 V 36.1 MILD 18.2 0.36 D0 72 
49 RAVI 50 M 78 81 M 20.9 N 19.9 0.36 D0 70 
50 NARENDHERAN 65 M 280 48 S 35.8 MILD 19.9 0.36 D0 62 
S. 
No 
NAME AGE SEX S.I 
FEV1 
% 
GOLD  
SPAP 
mmHg 
PHT  
TAPSE 
mm 
TEI 
LV 
DD 
EF% 
51 PERUMAL 68 M 150 46 S 36 MILD 20.9 0.36 D0 59 
52 RAJENDRAN 54 M 70 67 O 37.9 MILD 21.2 0.36 D1 56 
53 KARIKALAN 52 M 270 58 O 19 N 21.9 0.36 D0 66 
54 CHELLAIYA 68 M 300 44 S 36.1 MILD 22.8 0.36 D0 59 
55 NATRAJ 45 M 280 54 O 36.2 MILD 16.9 0.37 D1 70 
56 HARIKRISHNAN 61 M 320 34 S 38.2 MILD 17 0.37 D0 65 
57 GOVINDASAMY 70 M 280 45 S 36.1 MILD 17 0.37 D1 71 
58 SUBRAMANI 57 M 320 18 V 35.9 MILD 17 0.37 D0 63 
59 MOHAN 55 M 260 32 S 37.2 MILD 17.8 0.37 D0 63 
60 MATHI MOSES 58 M 150 43 S 39.4 MILD 18 0.37 D1 61 
61 SHANMUGAM 67 M 90 54 O 23.4 N 22.4 0.37 D0 69 
62 POONGAVANAN 50 F   21 V 19 N 23.8 0.37 D0 65 
63 RAMADOSS 66 M 280 55 O 18.9 N 24.3 0.37 D0 58 
64 SAMINATHAN 70 M 150 51 O 19 N 18.4 0.38 D1 56 
65 PADMANABAN 55 M 180 46 S 36.4 MILD 18.4 0.38 D0 67 
66 NAINIAPPAN 65 M 300 32 S 36.1 MILD 18.9 0.38 D0 62 
67 KONDALRAO 66 M 80 55 O 37.3 MILD 19.2 0.38 D1 56 
68 HEMA 51 F   45 S 38.4 MILD 19.4 0.38 D0 65 
69 NARAYANAN 70 M 300 64 o 35.8 MILD 22.1 0.38 D0 59 
70 RAJAN 60 M 270 51 O 38.5 MILD 24.7 0.38 D0 65 
71 NANDEESWARAN 53 M 300 39 S 37.4 MILD 18.3 0.39 D0 66 
72 CHANDRA 60 F   29 V 36.1 MILD 24.3 0.39 D0 66 
73 KALIDASS 68 M 280 59 O 22.8 N 20.3 0.4 D1 65 
74 MURUGAN 70 M 60 91 M 35.1 MILD 19.1 0.41 D1 60 
75 GAJENDRAN 78 M 280 33 S 35 MILD 19.8 0.41 D0 70 
76 MARIAPPAN 55 M 105 83 M 36.1 MILD 19.6 0.44 D0 68 
77 BALU 48 M 300 45 S 36.4 MILD 19.2 0.45 D1 50 
78 AADHIMOOLAM 67 M 520 25 V 45.9 MOD 21.4 0.45 D2 48 
79 SUSEELA 65 F   45 S 46.3 MOD 16.2 0.46 D0 66 
80 KANTHA 60 F   36 S 46 MOD 16.4 0.46 D0 66 
81 SAMY 69 M 400 33 S 46.2 MOD 17.9 0.46 D0 60 
82 MANI.E 68 M 400 37 S 47 MOD 18.9 0.46 D0 59 
83 JOSEPH STALIN 69 M 240 43 S 45.1 MOD 18.9 0.46 D0 60 
84 ELUMALAI 85 M 280 43 S 46.2 MOD 19.8 0.46 D0 59 
85 PALANI 65 M 600 30 S 45.1 MOD 20.8 0.46 D0 60 
86 IRUSAPPAN 62 M 320 32 S 46.4 MOD 24 0.46 D0 66 
87 VIJAYA 65 F   24 V  47.2 MOD 16.3 0.47 D1 65 
88 NANDAGOPAL 50 M 460 29 V 46.1 MOD 17.9 0.47 D2 36 
89 FAZOOL RAHMAN 54 M 370 29 V 46 MOD 18 0.47 D1 62 
90 SAM 64 M 120 45 S 36.2 MILD 19 0.47 D0 68 
91 DHARMARAJ 62 M 300 47 S 47.3 MOD 19.9 0.47 D1 61 
92 THILAGA 60 F   22 V 46 MOD 19.9 0.47 D2 67 
93 SAMMANDHAN 61 M 450 29 V 46.2 MOD 20 0.47 D0 69 
94 ANTONY 52 M 400 38 S 47.3 MOD 20.3 0.47 D0 65 
95 RAJAVELU 86 M 200 35 S 45 MOD 17 0.48 D1 61 
96 SEKAR 55 M 270 56 O 37.4 MILD 18.1 0.48 D1 64 
97 DEENAN 65 M 170 43 S 47.3 MOD 18.9 0.48 D4 25 
98 HARI 61 M 300 34 S 38.4 MILD 19.2 0.48 D0 69 
99 JAKKARIYA 77 M 340 29 V 45 MOD 24.3 0.48 D1 58 
100 JOHNN BASHA 58 M 420 32 S 19 N 17.1 0.565 D1 58 
  
 
 
KEYS TO MASTER CHART 
 
S.I - SMOKING INDEX 
TAPSE - TRICUSPID ANNULAR PLANE SYSTOLIC EXCURSION 
SPAP - SYSTOLIC PULMONARY ARTERIAL PRESSURE 
LVDD - LEFT VENTRICULAR DIASTOLIC DYSFUNCTION 
PHT - PULMONARY HYPERTENSION 
GOLD - GLOBAL INITIATIVE FOR OBSTRUCTIVE LUNG DISEASES 
EF - EJECTION FRACTION 
FEV1 - FORCED EXPIRATORY VOLUME IN 1 SECOND 
 
 
  
PATIENT CONSENT FORM 
STUDY DETAIL   : 
 
STUDY CENTRE   : 
 
PATIENT’S NAME                      : 
 
PATIENT’S AGE   : 
 
IDENTIFICATION NUMBER : 
 
 I confirm that I have understood the purpose and procedure of the above study. I have 
the opportunity to ask questions and all my questions and doubts have been answered to my 
complete satisfaction. 
 I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. 
 I understand that the sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my permission to 
look at my health records, both in respect of the current study and any further research that 
may be conducted in relation to it, even if I withdraw from the study I agree to this access. 
However I understand that my identity would not be revealed in any information released to 
third parties or published, unless as required under the law. I agree not to restrict the use of 
any data or results that arise from this study. 
 I hereby consent to participate in this study. 
 I hereby give permission to undergo complete clinical examination and diagnostic 
tests including haematological, biochemical, radiological tests. 
 
Signature/thumb impression: 
Patient’s name and address:                                              
Place:                              Date: 
 
Signature of the investigator: 
Name of the investigator:                                                  
Place:                              Date: 
  
÷{õ¯õÎ J¨¦uÀ £iÁ® 
Bµõ´a] ø©¯®: Aµ_ RÌ£õUP® ©¸zxÁU PÀ¿¶ ©¸zxÁ©øÚ 
÷{õ¯õÎ°ß ö£¯º:      ÷{õ¯õÎ°ßÁ¯x: 
£vÄGs: 
÷{õ¯õÎRÌPshÁØÖÒPmh[PøÍ () ö\´¯Ä® 
1. ÷©ØSÔ¨¤mkÒÍBµõ´a]°ß ÷{õUPzøu²® £¯øÚ²® ¬ÊÁx©õP 
¦¶¢xöPõs÷hß. ÷©¾® GÚxAøÚzx \¢÷uP[PøÍ²® 
÷PmkAuØPõÚÂÍUP[PøÍ²® öuÎÄ£kzvUöPõs÷hß. 
 
2. ÷©¾® C¢uBµõ´a]USGÚx ö\õ¢u Â¸¨£zvß ÷£¶À £[÷PØQ÷ÓßGßÖ®, 
÷©¾® G¢u ÷{µzv¾® GÆÂu ¬ßÚÔÂ¨¦ªßÔC¢uBµõ´a]°¼¸¢x Â»P 
¬Êø©¯õÚE¶ø© EÒÍøu²®, CuØSGÆÂu \mh ¤øn¨¦® CÀø» 
Gß£øu²® AÔ÷Áß. 
 
3. Bµõ´a]¯õÍ÷µõ, Bµõ´a] EuÂ¯õÍ÷µõ, Bµõ´a] E£¯zuõ÷µõ, Bµõ´a] 
÷£µõ]¶¯÷µõ, KÊ[Sö{Ô ö\¯ØSÊ EÖ¨¤ÚºP÷Íõ G¨÷£õx ÷Ásk©õÚõ¾® 
GÚxAÝ©v°ßÔGÚx EÒ÷{õ¯õÎ 
£vÄPøÍC¢uBµõ´a]UPõP÷ÁõAÀ»xGvºPõ» ¤Ó Bµõ´a]PÐUPõP÷Áõ 
£¯ß£kzvUöPõÒÍ»õ® GßÖ® ÷©¾® C¢u |£¢uøÚ {õßCÆÁµõ´a]°¼¸¢x 
Â»QÚõ¾® uS® GßÖ® J¨¦UöPõÒQ÷Óß. B°Ý® GÚxAøh¯õÍ® 
\®£¢u¨£mhG¢u £vÄPÐ® (\mh§ºÁ©õÚ ÷uøÁPÒuÂµ) 
öÁÎ°h¨£h©õmhxGßÓEÖvö©õÈ°ß ö£¯¶À C¢uBµõ´a]°¼¸¢x 
QøhUP¨ö£Ö® ¬iÄPøÍöÁÎ°h ©Ö¨¦ 
öuÔÂUP©õm÷hßGßÖEÖv¯ÎUQß÷Óß. 
 
4. C¢uBµõ´a]US {õß ¬Ê©Úxhß \®©vUQß÷ÓßGßÖ® ÷©¾® Bµõ´a]U 
SÊÂÚº GÚUS AÎUS® AÔÄøµPøÍuÁÓõx ¤ß£ØÖ÷ÁßGßÖ® 
EÖv¯ÎUQß÷Óß. 
 
5. C¢uBµõ´a]USz ÷uøÁ¨£k® AøÚzx ©¸zxÁ¨ £¶÷\õuøÚPÐUS® 
JzxøÇ¨¦ u¸÷ÁßGßÖEÖv¯ÎUQß÷Óß. 
 
6. C¢uBµõ´a]US ¯õ¸øh¯ ÁØ¦Özu¾ªßÔ GÚx ö\õ¢u Â¸¨£zvß ÷£¶¾® 
_¯AÔÄhÝ® ¬Ê©ÚxhÝ® \®©zvUQß÷ÓßGßÖCuß ­»® 
J¨¦UöPõÒQ÷Óß. 
 
 
÷{õ¯õÎ°ßøPö¯õ¨£® / ö£¸ÂµÀ øP÷µøP: 
Ch®:     ÷uv: 
Bµõ´a]¯õÍ¶ßøPö¯õ¨£®: 
Ch®:     ÷uv: 
  
  
 
 
  
   
 
 
